CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database

Tilloy V

References:

Rank: 2 - First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.(Aug 2022)

Mutations:

Mutant	Gene	Virus	Reference
A4T	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
D12E	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
G16A	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
E17A	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
E17del	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
Q23K	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
D24G	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
S28F	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
E39D	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
D40N	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
E42G	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
G56D	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
G61D	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
L70I	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
A95V	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
V113L	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
S153P	UL51	Human betaherpesvirus 5	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)

Tilloy et al., 2024

Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230